Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

Agostini’s Ltd has changed its name to Agostini Ltd. The name change follows a meeting of its shareholders today.

Sygnature Discovery has appointed Fraser McIntosh as Vice President, In Vivo Pharmacology. Fraser will lead the company’s in vivo drug discovery operations worldwide.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (ATYR – Research Report), Crispr Therapeutics AG ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to use approximately $25 million to ...

LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company specializing in the development of treatments for ocular conditions and currently valued at $37 million, has ...

As a market leader, Rocket Companies rebranding comes in the foreground of several court battles and fluctuating earnings ...